Europe — EMA
Palonosetron Reig Jofre
Palonosetron, the active ingredient in Palonosetron Reig Jofre, is a 5-HT3 receptor antagonist presented as an intravenous solution for IV use.
Request sourcing
What is Palonosetron?
Palonosetron, the active ingredient in Palonosetron Reig Jofre, is a 5-HT3 receptor antagonist presented as an intravenous solution for IV use. It is employed to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
GNH USA supplies Palonosetron Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Palonosetron used for?
Palonosetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting related to specific therapeutic pathways.
- Chemotherapy‑induced nausea and vomiting (CINV): Provides effective prophylaxis of acute and delayed CINV in adult patients receiving highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after surgical procedures requiring general anesthesia. - Radiotherapy‑induced nausea and vomiting: Helps ...
